<SEC-DOCUMENT>0001144204-14-016295.txt : 20140318
<SEC-HEADER>0001144204-14-016295.hdr.sgml : 20140318
<ACCEPTANCE-DATETIME>20140318080514
ACCESSION NUMBER:		0001144204-14-016295
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140318
FILED AS OF DATE:		20140318
DATE AS OF CHANGE:		20140318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		14699341

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v371987_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF
1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of March, 2014 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number </B>_________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Novogen Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>16-20 Edgeworth David Ave, Hornsby, NSW
2077, Australia </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange on which the registrant&rsquo;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant&rsquo;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission
or other Commission filing on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
No </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Novogen Limited </B>(Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Lionel Mateo </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lionel Mateo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date 18 March 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v371987_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><META content="text/html; charset=utf-8"></META></head><body style="font-size:10pt;font-family:Arial;color:black;"><div style="width:100%;margin-left:10pt">
<p style="text-align:center"><b>Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo</b></p>
<br /><br />
Experimental drug designed to fight abdominal cancers passes important test</div><div style="width:100%;margin-left:10pt;"><div style="margin:0;margin-top:16pt;"><p>SYDNEY, March 18, 2014 /PRNewswire/ -- Novogen Limited [ASX:NRT; NASDAQ:NVGN] and its joint venture company with Yale University, CanTx Inc, today announced an important milestone with lead candidate drug, Trx-1, demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells. </p><div style="TEXT-ALIGN: left; WIDTH: 100%"><img src="ny36990logo.jpg" style="WIDTH: 400px; HEIGHT: 147px" id="prni5decleft" title="Novogen Logo" border="0" alt="Novogen Logo" align="middle"></div><p>CanTx is seeking a novel approach to the treatment of abdominal cancers, by developing a product to be administered intra-peritoneally with the ability to seek out tumor cells and to eliminate the full hierarchy
of cells within tumors. The final product is envisaged to be Trx-1 in a &#39;smart&#39; drug delivery system.</p><p>The first key step in that process was confirmation that Trx-1 alone would be effective. The study reported on today provides that confirmation.</p><p>The study was conducted in the laboratories of Gil Mor, M.D., Ph.D, Professor of Obstetrics, Gynecology and Reproductive Science at Yale School of Medicine, and involved an animal model for ovarian cancer considered to be highly representative of the clinical situation. In this model, ovarian cancer stem cells obtained from a patient with refractory ovarian cancer are injected intra-peritoneally, where they grow in a disseminated manner, forming multiple tumors in locations that resemble those observed in patients with ovarian cancer. </p><p>&#34;Until now, we have not been able to identify a drug from any company that is
effective in this model. So it is very exciting to observe an anti-tumoral effect with Trx-1,&#34; Prof. Mor said.</p><p>&#34;But this is just the first step. We needed to establish the anti-cancer credentials of Trx-1 on its own. The second step that we hope to report on very soon is the final product of Trx-1 in a &#39;smart&#39; delivery system, rather than the standard cyclodextrin carrier used in this study. The advantage of an intra-peritoneal product is that it delivers drug directly to where it is needed,&#34; Prof. Mor continued. &#34;And while we are focusing for the moment on ovarian cancer, there is every reason to believe that the same strategy will be applicable to other types of tumors contained within the abdominal cavity, such as pancreatic and colorectal cancers.&#34; </p><p>&#34;This represents a key inflection point for the Company and its super-benzopyran drug
technology platform. The usual test of showing that a drug can stop the growth of standard cancer cell lines implanted under the skin of athymic mice is an important STOP: GO step for any experimental anti-cancer drug, but hardly an ultimate test,&#34; said Graham Kelly, Ph.D., Novogen and CanTx CEO. &#34;Prof. Mor set us an ultimate test by setting out to replicate as much as possible the clinical situation. These ovarian cancer stem cells produce tumors comprising daughter cells that are highly chemo-resistant as well as being highly aggressive and tumorigenic.&#34;  </p><p>&#34;Trx-1 had shown high potency against human ovarian cancer stem cells and their daughter cells in vitro, leading us to believe that it is the first drug to be effective across the full spectrum of ovarian cancer cells at the same dosage, but this was the evidence that we needed to progress this drug into the
clinic,&#34; Dr. Kelly said.</p><p><b>About Ovarian Cancer
<br /></b>The American Cancer Society estimates that over 22,000 women will be diagnosed with ovarian cancer during 2013 and 14,230 American women will die from the disease. It ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. This cancer mainly develops in older women. About half of the women who are diagnosed with ovarian cancer are 63 years or older. It is more common in white women that African-American women.</p><p><b>About Novogen Limited
<br /></b>Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange (&#39;NRT&#39;) and NASDAQ (&#39;NVGN&#39;).  The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.</p><p>Further information is available on the Company&#39;s website, www.novogen.com.  </p><p><b>For
Further Information Contact:</b></p><div>
<div><table style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt" border="0" cellspacing="0" cellpadding="0"><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 5.4pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>Investors</b></font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black">&#160;</font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 5.4pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE:
8pt"><b>Media</b></font></font></p></td></tr><tr><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 5.4pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>In the USA</b></font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">David Carey/Tanner Kaufman</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Lazar Partners </font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">+1 212-867-1762 </font></font></p><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Novogen@lazarpartners.com</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black">&#160;</font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>In Australia</b></font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Rudi Michelson </font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Monsoon Communications </font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">03 9620
3333</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">rudim@monsoon.com.au&#160; </font></font></p></td><td style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; PADDING-LEFT: 5.4pt; PADDING-RIGHT: 6pt; VERTICAL-ALIGN: bottom; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt"><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>In the USA</b></font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Hollister Hovey/Allison Parks</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Lazar Partners </font></font></p><p style="MARGIN: 0in"><font
style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">+ 1 212-867-1762</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Novogen@lazarpartners.com</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black">&#160;</font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>In Australia</b></font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Dr. Douglas Pretsell</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Instinctif
Partners</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">+61 (0)3 9657 0706</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black">&#160;</font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt"><b>In ROW</b></font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Sue Charles/Stefanie Bacher</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY: Arial; FONT-SIZE: 8pt">Instinctif Partners</font></font></p><p style="MARGIN: 0in"><font style="font-family:Arial;font-size:8pt;color:black"><font style="FONT-FAMILY:
Arial; FONT-SIZE: 8pt">+44 (0)20 7457 2020</font></font></p></td></tr></table></div></div><p>Logo - http://photos.prnewswire.com/prnh/20131220/NY36990LOGO</p>
<br /><br /><p> </p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ny36990logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ny36990logo.jpg
M_]C_X``02D9)1@`!`@```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`0$"`0$!`@("`@("`@("`0("`@("`@("`@+_
MVP!#`0$!`0$!`0$!`0$"`0$!`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@("`@("`@("`@("`@("`@("`@+_P``1"`"3`9`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H
MI,_Y_P`]>E+0`4449'/MU_S^-`!11D'H<T4`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%(<'@]_P#]?]*`/-OC%\5_!GP*^%GC
M[XP_$+4TT?P5\./"VK>+/$-\VTNMAI-L\YM[6)B#<ZC<3"*WMH5R\]Q=10H"
M\B@_Q,ZY_P`'''[>-_K>LWOA[2/@QH?A^\U;4KG0=%O?`UYJ5[I&BSWDTFE:
M;>ZB?$H^WWL%@T$<TP`$DD;.``0*^T?^#CK]N2263PI^PQ\/=5"1*=,^(OQY
MNK28K)(%9+OX>_#Z9HY"!`7#:WJ,;*')@T4))Y37<4O\FHZ=<^YX/XU^2\9<
M4XVCF*P&5XN6'A@U:K*#MS5)6;C?72"5O\3EV/\`2?Z+?T=^&,RX'J<8>(?#
ME#.\1Q+.,\#1Q47)4,'3NHUE%.-IXF;E.[O^ZC2:MS,_>7_B(M_X*$_W/@?_
M`.&XO/\`YIZT]!_X..?V\;#7=$O_`!%HGP7\1>';+6=*NO$&@6/@J\T2_P!=
MT&VOK>?6M&T_6CX@F&CZC<Z8ES#;W;03I:S3).\$Z(8G_`<D#DTAYP.AZX(!
MP`,#\,_C7R$>*>(8RC+^U:KMK9M-/U31_3-7Z/'@G4I5*7_$.<MA[1./-&G-
M25U:\6IW36Z:::9_JP_![XL>"OCK\+?`?Q@^'.JKK/@GXB^&-*\5>';_`&"*
M9[#5+9)A;7MMN8V6IV\QFM[JW8E[>YM987^:,UZ37\E'_!N+^W)&/^$K_87^
M(6ILLP;4_B-\![ZZDREQ`Y:Z^('P_P`L?W=S#)C6;#^&:*YU2(^6UK"+G^M?
M/^?4>O\`/\J_<\DS2GG&6X;'4[*516G%?9J+2:]+ZJ_V6F?Y#^+/A[CO##CO
M/.$L8I3H82I[3"59*WM\'5O+#U4]$WR^Y4MHJL)I)6"BBBO6/S<****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KP']J7]H#PU^RQ^S[\5?C_
M`.++&[U;1_AEX3O]?&BV+O#=Z]JOR66@Z##=K;3#3C?:Y=:?:FZ>)X[5;LSR
M(R1E3[]7&?$7X?\`A'XK>`_%_P`-/'VBVGB/P7X[\.ZMX5\3Z'>^8+?4M%UJ
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M`OXI>`/C'\.M0_LSQO\`#7Q3I7B[PY=,Q6%KW2[@2R6%X%0E]-N[3[3:72`$
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M$4[Q2J^Z_:IO[RHK^<W_`(?_`&G_`/1L6J_^'.T[_P"9.D_X?_:?_P!&Q:I_
MX<[3O_F3K]X_U"XI_P"A8_\`P.'_`,D?Y,_\3(^#W_15K_PGQ'_RL_HSHK\@
M/V,?^"MO@K]J[XP)\'M:^&MU\*M9UC1+W4/!]_?^*[/Q!9^(M7TLBXO?#NV+
M2;1K+4&TO[1<VY_>)*-/GC)27R5E_7X=!_G^E?/9EE>.RC$_5,PH/#U^52L[
M-.+V::NGVWT::Z'Z;PGQCP[QQE?]L\,YC',\O525)SBI1<:D+<T90FHRB[--
M76J::T8M%%%>>?3A1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2$X!/\Z6
MB@#^=?\`X.$OV'%^-OP`L/VJ?`NDM+\3?V=;2XD\8K:0>9+XE^"MY(\_B!+B
M.-=\EYH.I-%JUO,698=/;68GB<SPRVO\/X_SWK_67U;2M.UW3-2T36+&UU/2
M=8L+O2]3TZ]A2XL[_3K^WDM;VRN[>0%9[:6WED1U8899"IZ\_P`W&N_\&R_[
M,&H:WK-_H_QZ^-'AO2+_`%74KW2O#UKI_@N\M=!TZ\O)KBRT6TN[O3?-N;6U
MMY(X(GES(R0*7);)K\UXMX1Q>9XVGCLKA"52JK58N2A[T;*,U?1W6C6^B>MS
M^\?HT_29X;X`X3QG!_B%C<12P>6U?:9;6IT:F):I5;NKAI*";A&E47M*;>EJ
MLHJR@K_Q7TW).<=.<COFO[/O^(8W]G'_`*.3^-W?_F#>`_\`Y65K:!_P;,?L
MNZ=KVAZEKGQX^-/B;1=.UG2K_5_#5Q9^#]-MO$FEV5_!=7WAZ\U'3=/6YL+&
M]MHI;:>:U>*ZCANG:VFAG$<R?*1X"XB<DG0IQ3W?M8Z+OI=_@?T?5^F1X'QI
MU)T\XQM6I&+<8++\0G*26D4Y))-O2[:6NK2.T_X-[_V(X/@7^SSJG[4GCC1A
M!\3OVB[2!_#5U>Q!;O0/@I8SI=Z#96)E0-:0:WJELNLW#*<7<-OI#,SQVMOM
M_,+_`(*>_M72_M1_M)ZS_86J&\^%_P`*'U+P+\/(H)R^GWK17<(\6>*X@`!)
M-J6KV$*I(0=UEI%D%(&_=^_W_!5/]I_2_P!E?]F.+X:?#][3P_X[^*NES_#W
MP-I>@P1::GA'P386%O8>)-<TZVLHT32+.RT.:WT_3Q$$,=SJ=N;9`EM(T/\`
M'.%"!555545555`"JJ@!0%'0`8XK^R_![A"CE>`AF$J=XX>/LJ#:MS/_`)?5
MGYRE[J[>]K:Q_P`X7T]_'O,_$/C/,,FEB7'$9M76-S",9.4:5)66!P%]+QHT
M5"<U9<S5.32;DA<_3\A110/?W_EQ^M?N1_G(=1X)\9^)/AUXP\,>/?!^IR:1
MXI\':YIOB/P_J49<_9-4TJZCNK9I8U93-:NT>R>/($L,CQ-\KFO[T/V7?C[X
M<_::^!G@#XQ^&_+@C\4Z/&=:TE9!)+X?\46#&P\2:!<,#EI+76+>[C5_^6L2
MQRCY9%S_``#U^V?_``19_:KE^%WQEU#]GGQ1J8C\#_&F?[7X8CNI2(-'^)UA
M9[8?LV3B./5]&M#;2ICY[G3+$J5/F>9^>>(F0+,\J>88>'-C,L3EIO*D]:D;
M=XZ37H^Y_3OT8/$E\(<9KAO,,1R9%Q8X4?>?NTL8M,/5UV]HVZ,]K\T&_@1_
M6+12#].V/3%+7\]'^G84444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4$9_S
MZ<T4>GUY_(T`9>M:QIGA[2-4U[6KZUTS1]%T^\U75M2O95@M+#3]/MY+N]N[
MJ5^(H([:*1W8G`5"3TK^,3]HG_@IO^TM\1OC/X_\5_"_XP>.?`7PXO=>N+?P
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M=KG)Z_\`+MTZ_G7Q_2Y/X8P0.X]/SQ7Z;_8V4?\`0KP__@FG_P#(G\G+CKC2
MZ:XMS)-?]1V)\O\`IY_PY^YWQ-W_`/!13_@GUI_QH67^V?VG?V/1<:+\1715
MEU[QA\.?):\N[Z]A@0-="31T75X9?++->>'=5MX2&N;C/X89#88$$$`@@@@@
MC@@@\C'IGZU]Q_\`!/;]IT_LN_M%^'O$6M713X9^.XH_A_\`%C3Y5$^GW/A3
M69Q';ZS?6;G9,^EZE)%=+(072UDOH4REU/'*O_!0?]E__AEK]HOQ!X;T2UV_
M#+QS`WQ!^$]];D3:9-X3UFYE:71;*\0LEP^EZF9[0Q[FE2T:PGD'EW<$DOBY
M0O[&S7$Y%-\N#Q7-B,'T23=ZU%=O9S?-%?R3[)'W?&7_`!G/"&5^(5&]7.\I
M]EEF>+><YQC;`8^;W:Q-*/L:DW_R^HW;<IMGPW1117UA^-+=:V%]_P#/2OU2
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MG=)5<EX(C"M3IRT6*S.H[8#"K^;]XO;U4KVI4G?='SK\2?\`@K%^V3XL\?\`
MC'Q)X+^*^M^`?!^L>(-1O/"G@NTTOPM<IX;\-M.T>BZ7/<W.CSO<ZBFGQV[7
MDGG.CW<LQB;R?+`XG_AZ#^W?_P!'#>)O_!+X0[?]R[7P/]?T`]/\<4E==/AS
M(J=.%-91AVJ:2NZ4&W9)7;<;MZ:MZM[ZGA8KQ/\`$3$XFOB:G&F9QGB)RFU#
M&UX03G)R:C"-11A%-Z1BDHJR221]\C_@J#^W@""/VAO$@92"N[0_!SIE3D%T
M;P[B1<CE3U!(-?UK_L9_M):-^U9^SWX%^+-BUI#KE[8#1O'>CVK[DT'QUHRQ
MVGB/3E0MN2U:[`NK0N`\EEJ%O*0I?`_@OK]>O^"._P"U4_P/_:$3X2>)=7-M
M\.OCM/9Z((;N?;I^D_$B)?L_A/58A(=MM<WZ_P#$IE*X-P]Q8(^\V\`C^2XV
MX1P6(R:IB<LP-/#8O`7J6IP4?:02]^+44KM)*2]++<_;?H_^-.?93QSALKXL
MS[$YIDO$?+A>;%UZE98?$.2]A4BZDI<BE)^SG9I6FI/X5;^OZOY,_P#@J?\`
MM\_MO_!G]NCXA_!SX!_%S7?#GA'0O!'A+Q)8>%=+\/\`A'4OL\,?PZM_%WBO
M4(Y=6T*>>5([2VU2]FS*PCAMI&4*B$5_67N&,YXXY]<],>M?R2_M31QS?\'#
M7P<MYHXYK>Z\6?!BSNH)HTE@N;2[^$4EO=VMQ#("L]O+;RRQR(X*NDC*P()%
M?@,;7=U>R/\`2_?8_8C_`()%_MLZC^V=^S,+WQYKD.K?&KX5ZU)X/^)\ABM+
M.\U(7GGZAX2\5R6%G&D<,&H:0)8]\<4<37>B7B(N8F`_5.OXZ="DE_X(Y?\`
M!6>[T-7N]%_9E^-DUO;+"_VB32K;X2^/-8DDT60"3/VH^#?&T=Q;Q3Y>Z@TR
MSN8_,D-[<K<?V)Q2QS11S0R)-#+&DL4L3K)'+'(H>.2.120Z,I!!!P000<4F
MK=+)@?SV_P#!>#]LG]I']DJ#]G%OV?/B9?\`P[;QMIOQJG\3FQTGP_JG]J2^
M%H_ALVA-)_;NE77DF`ZYJF/+V;OM1W[MJX_>?X?ZE>:QX#\$ZOJ4YN=0U7PC
MX;U&^N65$:XO;[1K*YNIF2-0JL\\KMA0`-V``*_E[_X.;O\`CV_9'_[!/[17
M_HCX0U_33\/=1L-'^$'@?5]5O+;3M+TOX;>&M1U+4+R9+>TL;"Q\,65S>7EU
M/(0L%M%;Q2.[L0JJA8D`4=%\_P!`/F+]N;]O[X)_L(>`+?Q+\1;B?Q'XX\1P
MWB?#SX4Z!=6T?BGQE=V859KEY9U=/#_AB">6!;S5+A&BA,JQP17=TT=K)^!/
MAK]J3_@MK_P4(DG\7_L^>&'^#GPDO[N=-$U+P[8Z'X0\)FT#/;B&S\?>/HWU
M'QI+&\&VXO-/1;<W&]H[>SC<6R>-_LN>"+__`(+*?\%+?B3\9/BI:ZC>_`3X
M=R0>+KSPSJ/G)#!\.K;5[W2/@O\`"^]BA?&GW&LKIVJ:CJ4((25=(UZ-92[(
MS_V8Z7I>FZ)INGZ/HVG6.D:1I5G;:=IFE:9:P6.G:;I]G"EO9V-A96L:1VEG
M%!%&D<4:JB(@55``%/2/2[\^@'\HNJ_LY_\`!P9\-K6?Q3I?QA\1>-;BTWSM
MHVB_%/PAXIO94C0L_D:)XGL88+OY`V(DW.YPJ(SE0>]_9`_X+C_$[P-\37^`
M/_!1;P:W@^^MM5@\/77Q1/AN\\&>(O`6L;MA@^*W@EK;RY]#D6:U?^UK".T:
MSA03SVE_;7#7MI_497XM?\%I/V&O!_[17[.'BOXXZ!H-C9?'#X#>&[_Q=8^)
M;.WAM]2\2_#W08I=3\6^$==N4VG4["WTE-0U'3Q,7>TNK.1;78+RY29IIZ.*
MU[`>_P#_``5(\??&[P/^Q3XP^-7[,/Q%NO"OBGX?W7A7Q[)KGAZVT/7[3Q#\
M/9[N/3O$")_:&G7D%SI@TG7(]32>$#C2$E\WR!(&SO\`@DE^UAXD_:[_`&._
M#GC?Q_KI\1?%'P;XK\4_#SXC:I)!96MS>ZWI=U#K>CWMQ:Z=;0P0R3^#_$'A
MR7$4:J=Y)P^\#XG_`.")7QEM?VLOV'OBW^RM\4+D:[)\+K:_^%]Y!>L+N>Z^
M#WQ4T#6(?#,4L<KDR6MO);>+M.@#$!8=$CB4!(P:^+_^"&/C/Q!^S9^VK^TA
M^Q9XXO)()=<&O:;#:73Y6;X@?!37-4L/M=HSLJ;K_P`):AK$SO#'_I2:9;,6
M:.WBPK:2OHT!_6_117DGQZ^,'A[]G_X+_$_XU>*8VN-$^&?@O7?%MS81SBUF
MU>XTNRDETW0K6Z:&1;:\O]4-G90R.C(DM^C.-@8U('X8_&_]L[]I?XK?\%=/
M`7['/[/7Q1U#P=\+/"&I^&=*^*]KHFD>'KZ348]"T^7Q_P#$R>XU#5M*NI;2
MX'A][?2HFC*""<;S&Y.ZOV*_:T_:[^#7[&'PJO?BO\9=9N+73VN/[*\,>&=&
MBMKWQ;XX\1O;RW,'A[PMIES=P)<WA@ADDEEFF@M;6&-IKFXBC`)_"_\`X-__
M`(0^(OB'XJ_:9_;Q^*DG]L^./B-XJU3P1X?U>2+RHIM4UW5AX^^+VN65L\C_
M`&>VN=;O/"EC8HNTV-MH5U:Q.\%P57Y!^)4>L?\`!7K_`(*VR_"S4]=U-_V?
MOA+K/B7P];1:5>2P6UC\*_AU?10^-+_1)H92MAK/BKQ3;6\#WZ8N_LU_8D$?
MV;;1V]N*NULE8#U6S_;U_P""O7_!0_7M;N/V/?AK/\)/A-::E+IUMJWA^TT1
MK"Q$+NK6VN_%OQ[90PZYX@$4Z-<PZ/:VRP`*JVN^-II=F_\`V7?^#@KPQ'/X
MEL?CAJ_B&^M_WZ:+IOQB\*ZC/.^=XCATS7]/AL9"&&"KR!.>NW)K^I7P/X'\
M'_#7PCX?\!>`/#FD>$?!OA33+?1_#OAO0K.*PTK2=-M5Q%;6MM"H`RQ=W=MT
MDLDKRRN\CNQZJIOV7Z@?R=_`'_@M3^U+^S3\5T^!_P#P49^&^K7&G6T]K9ZO
MXID\)'PG\4_!D-T42U\27>C6,2:?\0_"3K"SYL8+>Z=9I;FUO;XPIIS_`-4'
M@[QAX7^(/A3P]XX\$Z[IOB?PCXLTBPU[PYX@TBY2[TW5](U*W2ZLKZSG3[\3
MPR*<$!E.5=5=64?!/_!2[]A7P;^VS^S_`.)-)71;"/XU>"-&U/7O@WXO2W1-
M6MM=LH&O3X/O+V.,R3^&=8:`VEQ`Q9(IKB&^C0SVR9_*S_@W?_:A\0ZQH'Q9
M_9!\:W-U(?AV!\1_AI#J+DWFBZ/JFJMI/Q!\%L))\1VMGXFETV_M841W2;Q!
MJN^188[:)&[-72LT!_0;\>/CQ\+OV:_A?XF^,'Q@\36WA;P1X6MTDO+R1&N+
MV_O;AQ!IVB:+IT.9=5UR[NF2*VMH@6=VRQ2-7=?YAO%W_!7+_@H?^VY\1-;\
M`_\`!/[X,:KX3\)Z=((XK[3?#6G>+_'4.GW;^58ZSX^\8Z\6\.^`C<-;/);V
MD87R@9XVU+4DB,D>+_P56\:_$#]O#_@H_P#"_P#8+\!^()['P7X(\1>'_"\L
M4;/+I%IXXU_2EU[Q[X^U6R239?7NB^#+B:VM1+AHEMKR"`(VH3>?_4-^SW^S
MU\*OV7_A7X:^$'P>\,6?AKPGX<M8U<Q11'5?$.KO#$FI>)O$^HI&'UKQ'>2Q
M+)<7,N6)"QQB.".*)'I%)M7;`_FPA^!?_!PU?0+KDGQ3UJTNI`)FTN;XD_#6
M"ZCD8%VB:QM+5K6,@MC"OMXP..ON'[*/Q0_X+@>"OVDOA'\,/VBO!-WXC^%'
MB_Q.UCXU\:^+/"/A/Q%HVA>&[:SO+[4;Z+QE\--1MQI&L&TLGCL%O)#$]S<1
M^=;7`!A;^DRBES7O[J`\`_:O\8>(_A[^S!^T1X\\(:G)HWBOP9\$OBAXI\-:
MO##;W$NEZ]H/@S6=3TG4(X+N&2*9X;ZU@D"R(\;&/#JRD@_RE_LM_M`_\%M_
MVQ_#/BCQ;\!OC-+XET7P;K]OX9U^;4O^%2Z!+;:O=:9;ZO%%%!JGAY&N(S97
M4+%U!4%MN<@U_4=^W%_R9A^UC_V;E\:/_5>>(:_&+_@VU_Y(#^TC_P!EJT+_
M`-5]HE$=%)VO:P'EW_"O?^#B[_HH%I_X/O@E_P#*2OTL_P"";WAO_@IAH7B?
MXGR?MZ^(X=<\/7&@^'T^'D<6H^!+TV^M)J-^VN.5\'V$+H&L39C,Y*<809R:
M_6>BDW?HD!_.Y_P6]_;'_:?_`&8?'O[.7A[]GCXEZAX#C\?Z)XQ.M6=CI7AO
M4!J^J6NM^'-/T<R2Z_I-SY!4ZC*@V-&O[XER<`CI?^",O_!1/XI_M"ZY\6_V
M;_VH?$5QK7QO\%:E?>)_"FL:K8:5HVIZMX;LKB+1/%WA"_T[2]/M8UU71-=A
MAG1PC23VNNR(RHNG&2?XY_X.07>/XG_LD21L5DC\.^/Y(V!P4>/Q%X2=&![,
M&`(]Q7#_`/!2?X<>./\`@G[^V=^S]_P4+^$&F"X\*_$F_P!`U_Q=IEO(UE9W
M'Q&LM$M8_B+X2U>>-7%G:^+_``;+?W5O>%)`FI?VG-+$6AMH[EJSC:VK_P"`
M!_7Y7Y8_\%A?C]\6_P!FW]CN^^)7P5\877@?QM%\1?!&BQZY9V.EZA,NF:K/
M?)?VOV?6+*XA*R+%&"QC+#;\I%?H9\)OBAX.^-?PT\#_`!9^'^HG5/!OQ!\-
M:9XH\/W;JD=Q]AU.W6;[+?0QRN+74[>8RV]U#O8P7-M+$S$H37Y(_P#!??\`
MY,!U+_LK7PW_`/2K4J2T:NNJ_,#[(_X)K_%CX@?'#]BOX(_%#XH^(9_%7CKQ
M5H^M7.O:]<6UC9S:A/:^)]9L('>WTVUA@B*VEK`F(XD!\O)&22?NBOS2_P""
M/_\`RCL_9P_[`'B+_P!3+Q#7Z6T/1M=@"HIG,<,LBHTC1QR.(TV[G*HQ"+O8
M`L2,#)`R1D@<U+2'IZY^G]:%HT[7L*2;C))\K:=GV\S^`C]J7XR^-_CY\?\`
MXH?$SX@:;J.@>(-5\5ZKI@\(ZJ'34/`^E^'KR?1=,\%7T+G]QJ>FVUD+:]4!
M5:_2[D5$$FT?/]?MC_P6E_94D^%GQFT_]H3PMIGE>!OC3.;/Q,]K$$M]'^)V
MGV)>=;A5X4:MHMF;N)A]^XTF_+[24+_B=_GTK^K.',;@\?DN7XC`P5/#^SC'
MD7_+MP2C*#\XM?/?J?XS>*'#^=\,\><2Y7Q!6EBLQ6)J577DK?6(5I.I3KKR
MJ0DG9:1=XK1!1117MGP(C`,I5@K*P(96`8,"#E2"/F!&>.]?T1?!WX2>(_\`
M@H[_`,$UO#.@>,KS2/!WQ#_9Y\?7?A+X6?%SQ_<7%CH&M>%M.M=)AN[>]UF*
MUN;E]-72KV/2+EEC=7U#PE:R/NDA8)^$7PE^&/BGXS_$OP3\*?!4`N/$WCOQ
M#I_A_32X)@LS>2C[7JEYCD6-G8)=74^.1%9OCG&?V4_X*G?%/PC\#/A;\(O^
M"=OP8N"GA[X>Z'HFO?%;4DPESJ-^D1O-!T>^,6!/JM[J4]YKVJ-C8LES8QQE
MC),EO\9Q,ZF,S#(\LR^7L\U]K]8C5MS?5Z5--3G*.TE._(HRTEKV/W;PFIX7
M)N'>/>+>):3Q?!RP:RZI@G-T_P"TL9B)PGAZ%.:3<)4'!XB5:%YTDDUI)GF'
M_#FKXK?]'+?LG?\`AP_$O_S$T?\`#FKXK?\`1RW[)W_AP_$O_P`Q%?CM179_
M9G$MO^2GC_X14?+^]ZGB?ZU^$[_YM-6N_P#J?8WR_P"G7J?TD_L9?\$X9?V6
M?'GC']I;XF^.OAC\;!\%?AYXD\6>#?`WP9U;4_%>MS^*H],U"2.^O8=3T.T$
M%PNDV6IP:9"B3-<7NHB;?!]A"W/\_GQ<^*OBGXW_`!+\:?%GQI="Y\1>/-=O
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MK3<:<\.N=)49>[%VE<_.[C]/UQ_C24?D>/\`/XT5]MIT/P%A3XI98)8IX)IK
M>XMYHKBWN;>62"YMKFWD6:WN;:>%@]O<QS)&\<B%71XU=6#*"&?Y]:]P_9Q^
M!7B;]I/XU^`?@SX5=K6\\8ZU%;:GK(@%Q'X<\-VBM>>(_$<MN2JS?9-)ANI(
MHF9%GN!#`77S=ZX8JO1P^'K5\3)1H48RE-O91BKN_P`NAZ&5X'&YIF.`R[+:
M4JV88VM3I480^*52<E&"C;6_,T^RW9_9G_P3Y^/'B?\`:,_94^&?Q%\:65[#
MXK-E=>&_$&HWEM]EC\2:AX8NI-&E\3V:DXECO5MHYI60+&;EIQ&J(%4?S]_M
M0C_CH@^"GI_PFGP/_3X4$U_5%\-_A]X7^%'@/PE\-O!.G)I/A/P3H.G>'="L
M%8R/#8Z=`L,;W$[?-=7LK!I9YG)DFFF>60EW)/\`*]^U#_RL0?!7_L=/@A_Z
MJ@U_)6-JX>OC<96PU+V&'JSG*$+_``Q<FXK[NG39:(_VMX:P>8Y=P_DN`S?&
M?VAFF#PM"GB*]K>UK0IQC.?G>2>KU?Q-)L_4[_@M5^QI#^U%^RCJWC;PQHIU
M#XM_L_Q:GX\\*BSMOM&HZ_X/%LA^(G@OR$4MJ$5SHEJE];0`%VO_``];)$#Y
MLD<M?_@B=^V3#^T[^RCIG@+Q/K9U#XL_L^)IO@7Q&+N<W%_KG@A[>7_A7'B\
M7#$F_AET:SFTV>8DRF[\-S239%Q#-<?L?)''+&\4J)+%*C1R1R*KQR1NI5T=
M&!#H5)!!&"#@U_'9XM2;_@CA_P`%9K/Q2([S1?V8_C8]UJ$TD$<[Z3:_"7QW
MK"IXEM$6W0BZ?P=XUA@NVM%#WD.F6=D_EN;^V:YY5JK=5J>V>R?\'-W_`![?
MLC_]@G]HK_T1\(:_;G]JS6+G0O\`@FI\9M0M,B9OV2M;TW*DAUBUOX;C1;AT
M8$%)%M]0E*L""I4,.0*_$#_@YEN;>\T[]C^[M)X;JTNM#_:%N;:ZMI8Y[>XM
MY[7X02P3P31,5FA>)E9'5BK*=PR"*_H1\?\`PVOOC'^Q9XJ^%&E&U76/B-^S
M5J7@S0Y;UBEG;Z]XA^&LFF:%=7+!AM@AU>XLI6R<8B.<C(I=%ZO]`/QB_P"#
M;?0+&V^`_P"TGXG$<3:KK7QGT'2+BXVK]H73-`\!:1<Z?9,X&?(2\UW5ID4G
M`:^D(ZU_2)7\HO\`P;A?&C3]#\2_M(?LV>(1+HOB/7W\/_%CPQI6IQRV=_-?
M^'8'\$_$70KBWNE5K36+&-/!TAM"//9?[1D,:K8W##^KJG/XG;8`JM>6=IJ-
MI=:??VT%[8WUM/9WMG=1)/;7=I<Q/!<VUQ!(I6:"2%W5T8%65R""#5FO(/V@
M/B_H?P`^"7Q4^-/B+RFTOX:^!_$'BMK6:7R%U2^TRPFDT?1(YCQ'<W^L&PLH
MB<#S;],D#)$@?RK?\&\$]UX0_;%_:5^&-G=S7.B_\*:U7[5*SEQJ%Q\,/BQX
M=\-:%>W!&!+-]D\9ZVRL1D?;92,;VS;_`."HMK??L)_\%8_@C^U_I5C=P^#?
MB#>^%/B7J[:;#(TFI+X2GT_P!\<=!L85F+7VL_\`"$W^D7R1GRXY;CQ9;1#`
M61E]#_X-MOA9K%UXG_:>^/&KK-/;6^C>"?A1I.L3J0^L:YJ=]?\`C?Q]*Y*@
M,52T\"2;T&UI-0F1@&BQ7WS_`,%\O@0/BG^Q=#\1]/L?M'B#X">.=)\8QSQI
MNFB\+>(@?"7BF$L`,6Q_M'2;E]S;`=*1RK,B8T;M-^>@'[:Z=J-AJ^GV.JZ5
M>VFI:7J=G;:CINHV%Q%=V.H6%["ES9WME=P,T=U:2V\D<D<B,R.DBLI*D$_S
M]_\`!PO^T*?`O[.GPY_9[T&YFE\5_'GQE)J>HZ9IP>XU&3P+\.VTZ^O4^R0(
MTCM>>+=8\*6MO&HWW+).D2R>5,J_9/\`P1R^.(^.'[!/P?DNKTW>N_"VWO?@
M_K89RTL`\"O'9>'HG7:NV,>$IM`$>!MV(`"=K5^/\3_\/"?^"[$=R<:Y\+/V
M6=5A^S2`?:])33?@/?3W5A)'+'&8WAN?C7K$US`^\K,I$D<CPA4J8Z/7H!^\
MW[)GP+N?V0_V&?`WPO$,=EXN\#_"?5-?\6FU>*4+\0]4TF^\4>)U2YMI72[6
MWU^[N+:*9#MEBL(Y%`#8K^?_`/X-N-+M]=^+W[3_`,0;WYM<3X?^"[$%S\WE
M^,?%&KZ[JL@4_P`1O-`L]QX/(!ZU_6CJNG6^L:7J6D7>3::I87NFW(&,FWO;
M:2UF`S_%Y<K>U?Q]_P#!$CQ&W[-W_!1+XZ?LU>-2-(U/Q-IGCOX:V5G).JVY
M\8?"WQ?-J-G;(Q3%S)+H%AK_`)!0A''*LP9`XGI+N[?F!_8I1114@%?Q[_\`
M!.VWMO`W_!<GX\>%]!@BLM&D\;_M2^'X+&V4I;6NDIXDU+5K2TCC&`J12:?:
MJ.I!C]Z_KQ\0:]I'A70=:\3Z_?6^EZ%X=TG4=<UK4KN18K;3])TFTFO]0O;B
M1B`D,5I;RNQ)P`A-?R+?\$5[?4_VB/\`@I=^T7^TZMC)#H5OI_Q4\=W,QMIQ
M;6VJ?&+QRY\/:>)3$!;WCZ4=<D2&0*QCL9L#,1%-;2?3_@H"7_@G*P\>_P#!
M<S]I3Q/K;>;J/A[Q_P#M;36)D)<M)H/CC4_AU8@E^OEZ"P">@C&W``Q_7W7\
M:W@/7+7]C#_@O1XM'C%UT3PK\0?C+XSLWU*\E^R:>FE?M#Z;-K>C:I=3L!&N
MGCQ;XDL@\C,(H#$TL[J(I-O]E//^'K^-.73T0!117\RO_!<G]J;]H[X"?M$?
MLS>&O@M\:?'WPQT#Q5X)O[[Q'I'A'6/[-LM:O8_'^FZ<ES?Q>2WG3"PEDB!R
M/D<BDDV[(#]Q?VX_^3,/VL?^S<OC1_ZKSQ#7\?'_``3._P""KGA7_@GG\._B
M7X&U_P"#^K_$JX^(?CBP\8P7^G>.-'\*1Z9!9>';'0392VNIZ/<M=2-)9-)Y
MBLJ@/M*Y&3_8/^W%_P`F8?M8_P#9N7QH_P#5>>(:_%__`(-N(XY/@!^T@)$1
MP/C7H1`=58`_\*^T49`(X."::VE\@.$_XB9?AO\`]&J^*/\`P\7A7_YE:_8/
M_@G9^WGH?_!0?X1^-?BQH/P\U#X;6O@WXGZC\,YM&U'Q/IWBN:^N=/\`"'@S
MQ<=52^TW3K9+>-H?&$4/DLC.#8M(7*R*J_>WV6V_Y]X/^_,?_P`34B1QQ@K&
MB1@G)"*$!.,9PH'.`/RI.W16`_D[_P"#D7_DI?[)?_8M?$+_`-2'PG7[U_M:
M?LOZ5^V!^QIXA^"-V+"#7=:\#:%J_@+5=2WK:Z)\0-!TVVU#PKJ$\\44CVMF
M]_&+6ZD2.5TL]1N"D4C80_@I_P`'(G_)2_V2_P#L6OB%_P"I#X3K^J/P;_R*
M'A7_`+%O0_\`TUVM'1>K_0#^<#_@@C^U-K>@77Q1_P""?_QDCOO#_C[X;Z_X
MG\0?#S2=<98K^T_LK4YM.^*?PWG1I&']K:3XB@DU&!8G=+BTU*_>#,.GO-+]
M9_\`!??_`),!U+_LK7PX_P#2K4J_.3_@L-\)/&O[%7[9OP;_`."B?P8LH[?3
M?%?BW1YO%*P*T-DGQ1\,V&V]TC6A&1C3?%7@*RU")V4_-)I.H&0QR/`TGV1_
MP6*^+_@_X^_\$IO!_P`9O`5X+WPE\1O&/PD\3Z2Q='GM%O7U+[;I5_L.(M4L
M=12ZL[N/K%<V,L1PRFFU=Q:ZM???8#[6_P""/_\`RCL_9P_[`'B+_P!3+Q#7
MZ6U^:7_!'_\`Y1V?LX?]@#Q%_P"IEXAK]+:4MWZ@%(2`,GM2T4@/G_\`:B^`
M7AS]IGX&?$#X.>(_+MT\4Z+,-$U9HO.D\/\`BBP(O_#6OP)GYGM=8@M)&3(\
MV)9(B=LC5_!?XV\&^)/AWXP\4>`_&.FR:1XI\':[J?ASQ!ISY86FJ:3=RV=V
ML4N,3VK21%X91\LT,B2IE'!K_1//UX_7\Z^+_BO_`,$^/V2/C9XZUCXE?$?X
M2:9KOC/Q!]C.LZQ'J_B'2GU"2QLX+"VGN+;2=6AB:Y%I:VZ-)LWN(AO8GFOO
M>"^,8\.?6L-C*<Z^"Q%IQ4+-PJ+1M*32M)6OKNEYG\U^/?@;7\4WD^:Y#B</
ME^?Y=S4:LZ_,H5L-*\HQE*G&<N>E4NX:.\9R3?PV_A8I?8\=.W7D'GVP,_A7
M]L`_X)0_L(?]$-L1QU_X2CQGGWY'B+UH_P"'47["'_1#K'D]/^$H\:>G3/\`
MPD7H*^^?BGD?3!XG[J?_`,F?SC_Q)[XA:?\`"YE=G_T\Q'W_`,`_(?\`X)G?
M#WPI^R]^S_\`%_\`X**_&"R1VTO0M5\+?!C1;KRXKB]S.=.O[W3A,R[M7UOQ
M(VGZ1:-P;>TL+N4.8;V79^)/Q%\?^*/BKX\\7?$GQK?G4O%GC?7M1\1Z]>9)
MC:_U&=IFM[4%1Y=C!%Y4%NF%$<%M&@50H`_H1_X+8^!/&?PX^"?[.?@GX<:1
M:Z#^S'X/OY]`O=#T-+H?V?XRL]-$7@H>(278SZ1_8\6N_99W)#:E<3/>R27<
M^G&OYO#UX]_3W]!7L<(2AFBQW$E2:GB,SFX15TW1H4GRPI>4OMSMHVUVN?!^
M-E*KPC4R#PKP]*5#+N$L/"O6FTXK'9ABX*IB,7K9RII-4:+>L8PDM.9H2@?Y
M_P`.***^UW/P4/3Z]NH]P2>O7_/%?NM^SO=Q_P#!03]@;QE^RCJI34?V@?V9
MK>#QI\$9;R>);[Q%X3T])8-+TBQO;@H(I8[>XO?#\J2OY20WFE322@,YMOPI
MK]`O^"7T/Q2E_;:^#/\`PJL`7::C?-XU>Y6=]-7X;?8I/^$Q74_L_(C:S,(M
M<_+_`&@UD37SG$^&53*ZF,A56'Q64OZS1J/11G35W%O?EJ1O!KKS'Z?X2YM/
M"\78;(Z^$GF.4<8K^R\;AH*\JE'%-1C4A';VF'J<E>G*WNN#>USX`DCDADDA
MGAFMYX))(+BWN89;:YM[B%VCGM[FVG59+:YCE5TDC=5>-T9'4,"*97]KGQ"_
MX)2_L6?$[QSXK^(?B?X=:N/$OC76[WQ'XADTCQQXOT73[K6M3D-QJ6H0Z7IN
ML1P6LUQ=M+/-Y:*))KB65@7=B>-_X<U_L(?]$[\5?^'+\>__`"^KYBGXH9$Z
M<'5H5X5&ES)132E;5)W5U>^MM3]?Q7T1/$:.(KQPF.R^KAHSDJ<I5YQE*',^
M23C[)\K<;-QN[/2Y_&N/H<]N!UXZY_SS7]4/_!%#]DL?#WX8ZI^TUXRTT)XN
M^+5LNF>`([A/WFC?#.TN/,.IP`J#'<ZYJL*SECO#:?I.GR0L@N;E7^B!_P`$
M;/V#AC=\.?%#+D;E;XE^/=KJ#DH^-?!V$<$`C@U^G&B:)I7AS1M*\/Z'8VVF
M:+HFG66DZ3IMI&L-I8:=IUO':6-G;0J,1016T,2(HX"Q@5\KQAQ[A<XRW^SL
MKC4I1KRO6<THWA&S459OXG9O;16UNS]A\#_HXYOP/Q6^*.,:N%Q57+J36"IT
M)NHE7J7C*M-RC%)TX75.ROS3YM''74`XP0/H.F.W6OY*/VHC_P`=$'P5_P"Q
MT^"'_JJ#7];%?#_C+_@GI^S9X\_:G\/?MC^(=&\53?&[PQJ'AS4])U.V\6ZE
M:Z!'=^%M%_L#2&G\.Q_N9T73OE=2<2-\YYK\L3M?S1_9)]P=:_*'_@L3^Q^_
M[5W[).O7GA?17U;XL?!%[[XE_#U+&W-QK.H6ME9#_A-?"FFQ11M+>2ZEX>MB
MT5I$#)=7VCV"QJ\JQJ?U>HH3L[]@/\[7]I?]IR3]H?\`8?\`V3O!FOZNE[XY
M_9AO_C-\+[Z.XN//O=1^'/BCPY\.-4^$VM6DA?$VFV^G^$O$VCG8'\G_`(1^
MV#LJS6^__0.^%G_),?AQ_P!B'X0]"#_Q3VG5^7GC3_@AG_P3W\<>)?%?BC4?
M`/C72[KQCK6N:]J6F^'/B%K>BZ%97GB&]N;_`%"WT32;8>5I&F"YNYS!;0[8
M+="L4*)$B(OZV:+I-GH.CZ5H>GJZ6&C:;8Z38K+(TLJV>G6L5G:K)*W,D@@A
M0,QY8@D]:&T]E9`?R0_\%/?V4OCA^P7^UC%_P42_9@L[B'P-K/C4^-_$5[I=
MI+?V?P^^('B*1[?Q78>--(M]ID\`>)KJ]OC+<;A`;GQ!=6<[VLLME)/^NO[+
M/_!:;]C7X_>%M$'C_P`=Z5\`?B=);6L.O^"_B->-INB)JVP+=MX9\;S0KI^L
M:.TZRF`SR6MX(E4W-I"Q&?UNU/3-.UK3K_2-8T^RU72=5L[G3M3TO4K6WOM.
MU'3[V%[:]L+^RNHWBO+.6WDD26*1621'*.I4D5^0GQG_`."&'[!'Q<U>[U_2
M?"?C/X-ZG>RRW%W#\)/%$.CZ!<W$BX!_X1?Q'I.J6.FVX;GR=.AL4)R2,DDN
MZ=E+H!]<>._^"BW[#/PYTF36?$O[4_P7DM4B>6.W\-^-M)\9ZG<E8VD$%II/
MA&>^N;BY8+A8UBW%B%QFOYP_VY?V]?BO_P`%6_B+X5_8Q_8H\#>)KKX8W^MV
MVIZYJ>I6[Z7JWC^YTN>-T\1>*2&:/P)\*=(WBY<W;FZO+EH7FCAEBMK&Y_23
MPM_P;P?L3:-J,%]XA\8_'CQ=;P3I*VD7/B[PUHFFWL:DE[:_DT/P=%>&)A@;
MK>[MI1@E9`3D?K5^S_\`LM?L_P#[+7AJ;PK\!OA=X9^'FFWGV<ZM=Z7;27/B
M#7WM5=;:3Q%XGU.6?4=>>/S9C']KN91&T\C(%,CEB\4]%=^8'#?L._LH^'?V
M,OV<?`WP/T6YMM4U32H;C6O''B*VBDAB\3>.=;9;KQ#JT2S`2"R$PBMK02!7
M6ST^W#JKAA7N?Q>^&7A[XS_"SXB?"7Q8C-X<^)'@WQ%X+U=XHX9+FUM/$.E7
M.F-J-D)T94U*U:X2XMI",Q7%K%(I#*"/1:*D#^(W_@G;^V'XC_X)W:=_P4+^
M!/Q&N+73?&7A_P`'^*=1\!Z;+<M'8O\`M#?#75KGX9SZ9H[2QB2]L]6AUC1=
M2BE`5?[,\`O<HCO<JC?J[_P;V?LZ3>#?@!\1/VF/%,$MQXO^/?BZ?2M!U*^C
M5KUO`/@:\O;:>^29X@T<VJ^.[SQ--=;':*>/1-.<XDB(7[.^-W_!'?\`8B_:
M`^*GC+XR?$'PAXS;QMX]U*'6/$L^@^/-9T33;S4XK&TT]KR/3+;,<$TD%E"9
M"OWGRQZU^@?PD^%G@OX(?#/P1\(_AWI9T?P1\/?#FG>%_#>GO/)=W$6FZ;"(
MDEO;V8E[[49I/-FN;B0F2>XN))I"7=C5-JWF]_D!Z)7\M'_!9[]AGXI_#3XN
MZ;_P4:_9A.L6NH:'>:+XF^*\?A>W=M>\!>*_!Z6ZZ5\7+&*%'6^\,S:59VT&
MN1R1;+-M,:[N?M5EJ-X+#^I>DQUSR#V(_P`\4D[`?AQ^Q;_P7$_9G^-'@K0-
M$_:*\4Z5\"?C/96=M8>(CKT%W:?#KQ1J,(CMY=:\+^(T6:'1X+F0K*;#49(9
M;9Y7BBENXHOM!_0GQ-_P4!_8B\(:0=<UO]JOX%)IZH)/^)9\1O#>OWK!LA$7
M2M`OKFZ:8G`""$N21A>17R_\?/\`@BU^P9\>M8O/$LOP[UGX2>)=1G-SJ&J_
M!;7(O!MG>S,S2,TOA2[TR^T6`M([-(]OIL$KYPTF`,?,VA_\&ZO[&%A?K<ZO
M\0_V@-;M(Y$D73T\3^#=*CF"N&:&[N;7P*TLD#*&#>6T+_-E9%(I^Z_(#XD_
MX*)?\%5]<_;9^Q?L5?L'^&/&7BO2OBA?)X=\7>*H-%N[#Q'\2;>5]Y\%^$-%
MN=D^B^#7BAEGUG4]0%L9K2!XGCM=-6\GNOV]_P""9'[#EC^PO^SG8>"=5_L[
M4?BUXXOU\9_%_P`0V!$\-QXBFMQ;Z9X:T^],:M/H6C:7MM+?`6.2XFOKY$5[
MV0M[=^S9^Q3^S'^R18W-M\!OA/H'@[4=1M!8ZOXJE-WKWC76+3S8YWM=2\7:
M[<7%_-9-<0P2&V6=+4/!&5A7RHPOU10WI9*R`_!G_@M'_P`$U?$/[5/AC1_V
M@_@7H[:G\<_AGHT^E:_X2L`(]0^)_@.WEEU&SMM(Y'G>-M(O7NI-/C!1[ZVU
M.XM`[W$.G1#Y0_8`_P""ZNB^#_"VF_`[]N:S\5Z;XB\%%?#>E_&6VT;4=5O;
MRTTIFL?[(^*WAE8_[3T[Q98RP"WEOH+>Y:[\IFU&WM+N&::\_J5-?"_[2W_!
M-S]CC]K#4;GQ#\7/@_I4OC:ZC1)OB#X1N[WP9XUG:*,Q03:EK&@31#7Y(XMJ
MI_:45XH6*-"I2-%5)K9H"QHG_!2K]@GQ#8#4M,_:N^#)M2NYA?\`BRUTBZCZ
M926QU98)HI`6`*M&""",<&OYD?\`@MW^T7\#OVB_VDOV:=8^!OQ.\+?$_2O"
M?A.XT/Q'J7A.];4++2M5O?B%IE];6,]SY2HT[VD;280MA0,GD5^K\W_!NO\`
ML2270DC^('[2$-H2Q>V_X3;P)+,"V>(KN3X9$H@!P-R.<#EC7O?PK_X(??\`
M!/CX7WUCJMQ\./%7Q-U73;F&[M+WXG^.=8UF!)H'$L;3:'H(TS3+S$JHP\ZQ
MDVM&"I'.:3C'57N!]G_MQ_\`)F'[6/\`V;E\:/\`U7GB&OYTO^"$W[7_`.S'
M^S5\%OCIH7QX^-7@CX7:UXF^*^DZUH.F>*K^>SO-4TFV\%:182ZA:QQVSA[5
M;V*6(MG.^)@1T)_J?^(W@/P]\4_A_P"-OAGXMANKCPM\0?"?B#P7XC@LKJ2Q
MO)M#\3:5=:-JL5K>Q?-:7#65Y.$D7YD8AAR*_)?_`(<*_P#!/+_H4?B:,<#_
M`(NGXA_^)I)K5/9@?37_``]3_P""=O\`T=S\(/\`P=7?_P`@5Z?\(?V[/V0?
MCWXSM_AY\&_V@/A[\0_&UW87^IVWAKPYJ4]SJ<VGZ9&LNH7:0R6J`Q11NK.<
M\`U\+?\`#A;_`()Y?]"C\3?_``Z?B'_XFO??V:O^"5?[(O[)OQ2L?C#\'=`\
M;:=XVT_2-7T.VN=<\<ZMKU@MAKD,=OJ"MIUXNQY3%&NUCRI&12TMY@?BM_P<
MB$?\++_9+Y_YEKX@_P#J0^$Q_.OZH_!O_(H>%?\`L6]#_P#39:U\C_M9_P#!
M/K]G#]M75_!&M_'71_%.J7_P^L]4L?#;^'O%FH^&XH;?6+NQO;X745D"+MC/
MI]MM+?="D#AC7VC864&FV-EIUJ&6UL+2VLK978NRP6L*00JSGEV$<:Y)Y)Y-
M%]$@/G/]L']F_P`._M9_LY?%#X$>(F@M3XS\/S#PYK,\/G?\(WXSTMEU/PCX
MB1`06%IKUK922JI!E@\Z$G;(:_B(M_CEXM\%_L6_M.?\$_?C0+C1?$?PO^+/
MASQY\/-+U&1S/HWB30?&\?A?XJ^`(I)),3V3S7T>LZ>L<:C,.JR[Y$N(5@_T
M#J_,S]H+_@D=^Q7^TO\`%;Q'\9_B7X-\5?\`"=>+1IK>(;SPQXTU;PY8:E=:
M7IUKI4&H3:;8CRAJ#6-E:K+*`&E,(=\N68M.V^J`F_X)`?\`*.S]G'_L`>(?
M_4R\0U^EM>1?`GX(^`OV<OA7X3^#7PQM-1L?`_@JUNK/0K75M3N-8U"*&\O[
MK4IQ<ZC=?/<L;J\F(+=`0.@%>NU+U;?<`HHHH`/\_P`NGY4F!C'3Z<8^E+11
M8`H_S^E%%`'BO[1'P2\+_M%?!KQ]\'O%T8&E^,M!NK"WOUC22ZT368\76AZ_
M8>8I"WUEJT%G<QY!5C;['#1LZM_!5\2_AWXI^$GQ`\8_#/QO9?V?XK\#Z_J/
MAW6[8+(D37=A,42\M/,&7T^YMV@N;9S_`*RWO(I!PP8_Z'QSV_`]OQK^<'_@
MN!^R4B_\([^UGX)T\K(SV'@GXNV=O"6696`A\'>-"(X_DGC?=I=Z2Q66.736
M0(UO,9_TKPWS_P#L_,993B*G+A<Q:Y+[1K)::]%->Z_-1/Y,^E7X:OB3ABCQ
MIEE#GS?AA-5U%7E6P4Y>]>VK>'F_:1[0E4^7\XU%2>5+_P`\I/\`OAO\*/*E
M&<Q2?]\-_AQ7[W[2G_.OO7^9_F^J%=_\N9_^`R_R(^..PX!)Z`GW]*_K1_X(
MR?LG+\(O@I<_'KQ=IOE?$#XX6UI=:%]IA"W&A?"VW/VCP_;0B5=T4^JW6_4[
MAP56:V?2XS&&M3)+_/\`_L$_LNWG[5W[2/@_X>7EE/+X&TA_^$R^)MTJNL47
M@G0[JW^U:=+(&4H^IZA-8::FT[P-3>4`K"Y']S=A8VFF6-GIVGVL%E8V%K!9
M65K;Q)#;VMK:Q)!;VT$,8`BA2)$554`*J@`8&*_)/$WB!0H4LCPM1.5=*I7L
M]H+X(.W\S]YKLEW/[4^B7X:2Q688SQ#S?"M8?+G+#Y?&<;*5>2M6KI-;4HOV
M<7_/.5M8%RBD!R`>/PI:_%3^_P`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`3(SCVSCVJG?:?8ZI:RV&IV5IJ%E.H6:TOK:&[MIE#
M*X6:"=620!E!&0>5!SFKM'XX_+^HH6C33LT3*,9Q<)Q4HR5FFKIKLT]&CB_^
M%;_#W_H1?!__`(36C?\`R'1_PK?X>_\`0B^#Q_W+6C'^=E7:45K[>M_S^E_X
M$_\`,Y?[.P'_`$!4?_!</\O(PM(\,^&]`:>30=`T317NEB2Y?2=+L=.>X2`R
M&%;AK.!#,J-+,5#9V^:V,;CG='OS2$9[D?2E''O]:SE*4I<TFY/NW=G13I4Z
M,%"E3C2@ME%))?))(****1H%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
,0`4444`%%%%`'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
